Epstein Becker Green and EBG Advisors presented a webinar series that examined the average manufacturer price (“AMP”) Final Rule and its effect on drug pricing and contracting.
The long-awaited issuance of the Final Rule addressing AMP under the Medicaid Drug Rebate Program provided clarity in some respects but left other issues open to interpretation. In the wake of the Final Rule, other regulatory developments showed signs of further impacting many of the same issues.
Using the AMP Final Rule as a baseline, presenters addressed the evolution of some of the most significant issues affecting drug pricing and contracting.
In this session, Constance A. Wilkinson, Member of the Firm at Epstein Becker Green, addressed how the AMP final rule can impact your business. This discussion examined various legal, operational, and financial factors, including the impact on fee-for-service arrangements with customers, value-based pricing, and reimbursement.